1384 LNK101, a highly differentiated T-cell engager (TCE) targeting CD3 and mesothelin (MSLN) in solid tumors

• Linda Santiago,
• Jane Carter,
• Ashok Bandaranayake,
• Colin Correnti,
• Ida Lin,
• Man Kid Chan,
• Scott Delbecq,
• Midori Clarke,
• Eric Gruff,
• William Bracken,
• David Meininger,
• Diana Hausman,
• Christopher Mehlin

Affiliations

Linda Santiago

1Link Immunotherapeutics, Seattle, WA, USA

Jane Carter

6Royal National Hospital for Rheumatic Diseases, Bath, UK

Ashok Bandaranayake

1Link Immunotherapeutics, Seattle, WA, USA

Colin Correnti

1Link Immunotherapeutics, Seattle, WA, USA

Ida Lin

1Link Immunotherapeutics, Seattle, WA, USA

Man Kid Chan

1Link Immunotherapeutics, Seattle, WA, USA

Scott Delbecq

1Link Immunotherapeutics, Seattle, WA, USA

Midori Clarke

1Link Immunotherapeutics, Seattle, WA, USA

Eric Gruff

1Link Immunotherapeutics, Seattle, WA, USA

William Bracken

2Independent Consultant, Mundelein, IL, USA

David Meininger

1Link Immunotherapeutics, Seattle, WA, USA

Diana Hausman

1Link Immunotherapeutics, Seattle, WA, USA

Christopher Mehlin

1Link Immunotherapeutics, Seattle, WA, USA